These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

142 related articles for article (PubMed ID: 31037517)

  • 1. Predictive and Accelerated Formulation Design Using Synchrotron Methods.
    Byrn SR; Chen XS; Smith PA
    AAPS PharmSciTech; 2019 Apr; 20(5):176. PubMed ID: 31037517
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Nanoamorphous drug products - Design and development.
    Jog R; Burgess DJ
    Int J Pharm; 2018 Dec; 553(1-2):238-260. PubMed ID: 30359685
    [TBL] [Abstract][Full Text] [Related]  

  • 3. In Situ Lipolysis and Synchrotron Small-Angle X-ray Scattering for the Direct Determination of the Precipitation and Solid-State Form of a Poorly Water-Soluble Drug During Digestion of a Lipid-Based Formulation.
    Khan J; Hawley A; Rades T; Boyd BJ
    J Pharm Sci; 2016 Sep; 105(9):2631-2639. PubMed ID: 26359590
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Impact of polymer type on bioperformance and physical stability of hot melt extruded formulations of a poorly water soluble drug.
    Mitra A; Li L; Marsac P; Marks B; Liu Z; Brown C
    Int J Pharm; 2016 May; 505(1-2):107-14. PubMed ID: 27012984
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pharmaceutical development of a parenteral formulation of conivaptan hydrochloride.
    Ban K; Sonohara R; Yoshida M; Sako K; Uchida S; Namiki N
    PDA J Pharm Sci Technol; 2013; 67(4):336-53. PubMed ID: 23872444
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Melt extrusion with poorly soluble drugs.
    Shah S; Maddineni S; Lu J; Repka MA
    Int J Pharm; 2013 Aug; 453(1):233-52. PubMed ID: 23178213
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Physical Stability of Amorphous Solid Dispersions: a Physicochemical Perspective with Thermodynamic, Kinetic and Environmental Aspects.
    Lin X; Hu Y; Liu L; Su L; Li N; Yu J; Tang B; Yang Z
    Pharm Res; 2018 Apr; 35(6):125. PubMed ID: 29687226
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Quality by design: discussing and assessing the solid dispersions risk.
    Chaves LL; Vieira AC; Reis S; Sarmento B; Ferreira DC
    Curr Drug Deliv; 2014; 11(2):253-69. PubMed ID: 24517867
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Physical stabilization of low-molecular-weight amorphous drugs in the solid state: a material science approach.
    Qi S; McAuley WJ; Yang Z; Tipduangta P
    Ther Deliv; 2014 Jul; 5(7):817-41. PubMed ID: 25287388
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A combined mathematical model linking the formation of amorphous solid dispersions with hot-melt-extrusion process parameters.
    Schittny A; Ogawa H; Huwyler J; Puchkov M
    Eur J Pharm Biopharm; 2018 Nov; 132():127-145. PubMed ID: 30240820
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Novel supercritical carbon dioxide impregnation technique for the production of amorphous solid drug dispersions: a comparison to hot melt extrusion.
    Potter C; Tian Y; Walker G; McCoy C; Hornsby P; Donnelly C; Jones DS; Andrews GP
    Mol Pharm; 2015 May; 12(5):1377-90. PubMed ID: 25730138
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Permeability of glibenclamide through a PAMPA membrane: The effect of co-amorphization.
    Ruponen M; Visti M; Ojarinta R; Laitinen R
    Eur J Pharm Biopharm; 2018 Aug; 129():247-256. PubMed ID: 29894814
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Primary packaging considerations in developing medicines for children: oral liquid and powder for constitution.
    Campbell GA; Vallejo E
    J Pharm Sci; 2015 Jan; 104(1):52-62. PubMed ID: 25393927
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Formulation of poorly water-soluble drugs for oral administration: physicochemical and physiological issues and the lipid formulation classification system.
    Pouton CW
    Eur J Pharm Sci; 2006 Nov; 29(3-4):278-87. PubMed ID: 16815001
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The Need for Restructuring the Disordered Science of Amorphous Drug Formulations.
    Edueng K; Mahlin D; Bergström CAS
    Pharm Res; 2017 Sep; 34(9):1754-1772. PubMed ID: 28523384
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Hot Melt Extrusion: Development of an Amorphous Solid Dispersion for an Insoluble Drug from Mini-scale to Clinical Scale.
    Agrawal AM; Dudhedia MS; Zimny E
    AAPS PharmSciTech; 2016 Feb; 17(1):133-47. PubMed ID: 26729533
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Biopharmaceutical classification of poorly soluble drugs with respect to "enabling formulations".
    Buckley ST; Frank KJ; Fricker G; Brandl M
    Eur J Pharm Sci; 2013 Sep; 50(1):8-16. PubMed ID: 23583787
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Improved Vemurafenib Dissolution and Pharmacokinetics as an Amorphous Solid Dispersion Produced by KinetiSol® Processing.
    Ellenberger DJ; Miller DA; Kucera SU; Williams RO
    AAPS PharmSciTech; 2018 Jul; 19(5):1957-1970. PubMed ID: 29541940
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Integrated Application of Quality-by-Design Principles to Drug Product Development: A Case Study of Brivanib Alaninate Film-Coated Tablets.
    Badawy SI; Narang AS; LaMarche KR; Subramanian GA; Varia SA; Lin J; Stevens T; Shah PA
    J Pharm Sci; 2016 Jan; 105(1):168-81. PubMed ID: 26852852
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Formulation performance and processability window for manufacturing a dual-polymer amorphous solid dispersion via hot-melt extrusion and strand pelletization.
    Hörmann TR; Jäger N; Funke A; Mürb RK; Khinast JG; Paudel A
    Int J Pharm; 2018 Dec; 553(1-2):408-421. PubMed ID: 30326284
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.